Jasper Data Show Potential Promise For Anti-CD117 Conditioning Agent

Jan 03 2023

• By Alaric DeArment

Listen to this article

Jasper announced data on the first three patients in the trial of briquilimab in sickle cell disease and beta-thalassemia patients, not long after another player, Magenta, announced a setback in its program.

Jasper announced early data for briquilimab, its CD117-directed monoclonal antibody • Source: Shutterstock

Jasper Therapeutics, Inc. made a significant achievement with positive early data on use of briquilimab as a conditioning agent for patients with sickle cell disease (SCD) and beta-thalassemia undergoing allogeneic stem cell transplant, especially after another company seeking to develop an alternative to the chemotherapy drugs traditionally used in the space, Magenta Therapeutics, Inc., announced a setback in its own program.

Jasper said on 3 January that the first three participants in an investigator-initiated Phase I/II study of briquilimab successfully engrafted...

More from Blood and Clotting

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes - Clone
Feb 04 2026
• By Urtė Fultinavičiūtė
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US
Syndax Achieves Commercial Status As Incyte-Partnered GVHD Drug Gets FDA Nod
Aug 15 2024
• By Alaric DeArment
US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.
Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III
Jul 24 2024
• By Jessica Merrill
The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.
Abecma Or Bust: 2seventy Sells Final Research Program To Novo
Jun 27 2024
• By Jessica Merrill
2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.